Completed PHASE4 INTERVENTIONAL 1-arm NCT02444637

Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage AD Having Coexisting svCVD

Open Label Trial of Rivastigmine Patch in Subjects With Mild to Moderate Stage Alzheimer's Disease Having Coexisting Small Vessel Cerebrovascular Disease

Sponsor: National Neuroscience Institute

Conditions Alzheimer Disease CVA (Cerebrovascular Accident)

Interventions Rivastigmine

Updated 7 times since 2017 Last updated: Mar 3, 2021 Started: Apr 30, 2015 Primary completion: Mar 31, 2019 Completion: Mar 31, 2019

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates Alzheimer Disease and CVA (Cerebrovascular Accident) and is currently completed. National Neuroscience Institute leads this study, which shows 7 recorded versions since 2015 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Apr 2021 — Jul 2024 [monthly]

Completed PHASE4

Status: Unknown Status → Completed
Jan 2021 — Apr 2021 [monthly]

Unknown Status PHASE4
Jun 2018 — Jan 2021 [monthly]

Unknown Status PHASE4

▶ Show 2 earlier versions

Jun 2017 — Jun 2018 [monthly]

Unknown Status PHASE4

Status: Recruiting → Unknown Status
Jan 2017 — Jun 2017 [monthly]

Recruiting PHASE4

First recorded

Apr 2015

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Neuroscience Institute

Data source: National Neuroscience Institute

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Singapore, Singapore